Fourteen weeks of liraglutide therapy in subjects with type 2 diabetes significantly improves first phase insulin secretion and maximal beta-cell secretory capacity

被引：0
作者：
Madsbad, S.
Brock, B.
Perrild, H.
Lervang, H. H.
Kolendorf, K.
Krarup, T.
Schmitz, O.
Le-Thi, T.
Zdravkovic, M.
Vilsboll, T.
机构：
[1] Hvidovre Univ Hosp, DK-2650 Hvidovre, Denmark
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Bispebjerg Univ Hosp, Copenhagen, Denmark
[4] Aarhus Univ Hosp, Aalborg, Denmark
[5] Roskilde Cty Psychiat Hosp Fjorden, Roskilde, Denmark
[6] Gentofte Univ Hosp, Hellerup, Denmark
[7] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0004
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
[41]   Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes [J].
Thomas, Melissa K. ;
Nikooienejad, Amir ;
Bray, Ross ;
Cui, Xuewei ;
Wilson, Jonathan ;
Duffin, Kevin ;
Milicevic, Zvonko ;
Haupt, Axel ;
Robins, Deborah A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02) :388-396
[42]   Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes [J].
Pennartz, Christian ;
Schenker, Nina ;
Menge, Bjorn A. ;
Schmidt, Wolfgang E. ;
Nauck, Michael A. ;
Meier, Juris J. .
DIABETES CARE, 2011, 34 (09) :2048-2053
[43]   Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [J].
Fehse, F ;
Trautmann, M ;
Holst, JJ ;
Halseth, AE ;
Nanayakkara, N ;
Nielsen, LL ;
Fineman, MS ;
Kim, DD ;
Nauck, MA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :5991-5997
[44]   Insulin therapy for type 2 diabetes: Rescue, augmentation, and replacement of beta-cell function (vol 70, pg 489, 2004) [J].
Mayfield, JA ;
White, RD .
AMERICAN FAMILY PHYSICIAN, 2004, 70 (11) :2079-2080
[45]   Relationship of obesity with glucose and beta-cell secretion during a standard meal in newly diagnosed treatment naive subjects with type 2 diabetes mellitus [J].
Luzio, S ;
Peter, R ;
Dunseath, G ;
Mustafa, N ;
Pauvaday, V ;
Owens, DR .
DIABETES, 2005, 54 :A448-A448
[46]   Cutting the brakes to prevent Type 2 Diabetes onset: augmenting insulin secretion and conserving pancreatic beta-cell mass by deleting Gαz [J].
Wisinski, Jaclyn ;
Reuter, Austin ;
Kimple, Michelle .
FASEB JOURNAL, 2017, 31
[47]   Dietary and genetic control of pancreatic beta-cell glucose transporter glycosylation promotes insulin secretion in suppressing the pathogenesis of type-2 diabetes [J].
Ohtsubo, Kazuaki ;
Takamatsu, Shinji ;
Marth, Jamey D. .
GLYCOBIOLOGY, 2006, 16 (11) :1116-1116
[48]   Determinants of Reversibility of Beta-Cell Dysfunction in Response to Short-Term Intensive Insulin Therapy in Patients With Early Type 2 Diabetes [J].
Kramer, Caroline K. ;
Choi, Haysook ;
Zinman, Bernard ;
Retnakaran, Ravi .
DIABETES, 2013, 62 :A243-A243
[49]   Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study [J].
Hompesch, Marcus ;
Kang, Jahoon ;
Han, OakPil ;
Trautmann, Michael E. ;
Sorli, Christopher H. ;
Ogbaa, Ike ;
Stewart, John ;
Morrow, Linda .
BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
[50]   Beta cell dysfunction in IGT and early type 2 diabetes: comparison of surrogate markers with first phase insulin secretion from an intravenous glucose tolerance test [J].
Festa, A. ;
Haffner, S. M. ;
Williams, K. .
DIABETOLOGIA, 2006, 49 :379-380
12345